FDA Determines Regulatory Review Period for ELFABRIO Patent Extension

Summary

The U.S. Food and Drug Administration (FDA) has officially announced its determination regarding the regulatory review period for ELFABRIO's patent extension, following the submission of patent extension applications to the U.S. Patent and Trademark Office (USPTO).